| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| F Leclercq, A Fille, B Albat, J Y Beigbeder, P Messner, A Thévenet, J Bringer, R Grollea. [Dilated cardiomyopathy in acromegaly worsening under octreotide treatment. Apropos of a case]. Annales de cardiologie et d'angeiologie. vol 42. issue 3. 1993-06-22. PMID:8498802. |
dilated cardiomyopathy associated with acromegaly is rare, but may improve with octreotide, a somatostatin analogue. |
1993-06-22 |
2023-08-12 |
Not clear |
| J A O'Hare, F Abuaisha, T Cotte. Experiences with octreotide in acromegaly. Irish journal of medical science. vol 162. issue 2. 1993-04-08. PMID:8444580. |
we report experiences in 3 patients with acromegaly while using the somatostatin analogue octreotide. |
1993-04-08 |
2023-08-12 |
Not clear |
| I Heron, F Thomas, M Dero, A Gancel, J M Ruiz, B Schatz, J M Kuh. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 76. issue 3. 1993-04-05. PMID:8095269. |
pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog bim 23014 in patients with acromegaly. |
1993-04-05 |
2023-08-12 |
human |
| Y F Shi, X F Zhu, A G Harris, J X Zhang, Q Da. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients. The Journal of clinical endocrinology and metabolism. vol 76. issue 1. 1993-02-17. PMID:8421099. |
this article reports the changes in gallbladder function examined by ultrasonography in 20 chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months. |
1993-02-17 |
2023-08-12 |
Not clear |
| S Ezzat, S G Ren, G D Braunstein, S Melme. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. The Journal of clinical endocrinology and metabolism. vol 75. issue 6. 1993-01-15. PMID:1281485. |
as the long-acting somatostatin analog octreotide attenuates polypeptide hormone hypersecretion, it has recently been used to effectively treat acromegaly and gastrointestinal carcinoid tumors. |
1993-01-15 |
2023-08-11 |
human |
| T C Chang, C C Chang, K S Tsai, T S Huang, W Y Tsai, M H Lin, F W Che. Clinical experience of octreotide in the treatment of acromegaly. Journal of the Formosan Medical Association = Taiwan yi zhi. vol 91. issue 6. 1992-12-18. PMID:1358345. |
to evaluate the efficacy and safety of octreotide (a somatostatin analogue) in the treatment of acromegaly, 10 patients were injected subcutaneously with octreotide, 50 micrograms, thrice daily before each meal for two days, followed by 100 micrograms thrice daily for six months. |
1992-12-18 |
2023-08-11 |
Not clear |
| M Riedel, T Günther, A von zur Mühlen, G Braban. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin? Clinical endocrinology. vol 37. issue 3. 1992-12-09. PMID:1358484. |
we studied the effects of different modes of octreotide therapy on the pulsatile pattern of gh release in an attempt to define better its regulation by growth hormone-releasing hormone (ghrh) and somatostatin and its effects on igf-i plasma levels in acromegaly. |
1992-12-09 |
2023-08-11 |
Not clear |
| A A Bulatov, I S Komolov, N B Smirnova, Iu K Trunin, S Iu Serpukhovitin, L K Dzeranova, E I Marova, I I Dedo. [Regulation of hormone secretion in primary cell cultures of human somatotropinomas]. Biulleten' eksperimental'noi biologii i meditsiny. vol 113. issue 4. 1992-11-06. PMID:1356509. |
the effects of somatostatin and thyroliberin (thyrotropin-releasing hormone; trh) on growth hormone (gh) and prolactin (prl) secretion were studied in short-term (0.5-3h) or long-term (21-24h) incubations using monolayer cell cultures of somatotropin obtained from surgical material of patients with acromegaly. |
1992-11-06 |
2023-08-11 |
human |
| S Ezzat, P J Snyder, W F Young, L D Boyajy, C Newman, A Klibanski, M E Molitch, A E Boyd, L Sheeler, D M Coo. Octreotide treatment of acromegaly. A randomized, multicenter study. Annals of internal medicine. vol 117. issue 9. 1992-11-03. PMID:1416572. |
to determine the effects of the somatostatin analog, octreotide acetate, in patients with acromegaly. |
1992-11-03 |
2023-08-11 |
Not clear |
| S W Lamberts, J C Reubi, E P Krennin. Somatostatin receptor imaging in the diagnosis and treatment of neuroendocrine tumors. The Journal of steroid biochemistry and molecular biology. vol 43. issue 1-3. 1992-10-22. PMID:1356013. |
somatostatin analogs are used in the control of hormonal hypersecretion and tumor growth of patients with acromegaly, islet cell carcinomas and carcinoids. |
1992-10-22 |
2023-08-11 |
Not clear |
| R Cohen, P Chanson, E Bruckert, J Timsit, A Legrand, A G Harris, P J Guillausseau, A Warnet, J Lubetzk. Effects of octreotide on lipid metabolism in acromegaly. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 24. issue 8. 1992-10-22. PMID:1526629. |
the somatostatin analog, octreotide (sandostatin), widely used in the treatment of acromegaly, is able to produce a decrease in levels of growth hormone (gh), insulin, and insulin-like growth factor 1 (igf1). |
1992-10-22 |
2023-08-11 |
Not clear |
| S W Lamberts, J C Reubi, E P Krennin. Somatostatin analogs in the treatment of acromegaly. Endocrinology and metabolism clinics of North America. vol 21. issue 3. 1992-10-13. PMID:1355729. |
somatostatin analogs in the treatment of acromegaly. |
1992-10-13 |
2023-08-11 |
Not clear |
| S W Lamberts, J C Reubi, E P Krennin. Somatostatin analogs in the treatment of acromegaly. Endocrinology and metabolism clinics of North America. vol 21. issue 3. 1992-10-13. PMID:1355729. |
medical therapy of acromegaly with the somatostatin analog octreotide is very successful. |
1992-10-13 |
2023-08-11 |
Not clear |
| G Faglia, M Arosio, N Bazzon. Ectopic acromegaly. Endocrinology and metabolism clinics of North America. vol 21. issue 3. 1992-10-13. PMID:1521513. |
patients with ghrh-induced acromegaly benefit from the administration of the long-acting somatostatin analog, octreotide, which reduces gh, igf-i, and ghrh, and may shrink the ectopic tumor, its metastases, and the secondary pituitary enlargement. |
1992-10-13 |
2023-08-11 |
Not clear |
| B Schindel, I Ashkenazi, R Keret, A Silbergeld, M Wasserman, M Lapidot, A G Harris, Z Laro. Effect of octreotide on 24-hour growth hormone and prolactin secretory patterns in acromegalics. Hormone research. vol 36. issue 5-6. 1992-09-15. PMID:1823080. |
four adult patients with active acromegaly underwent studies of their 24-hour secretory pattern of hgh and prl prior to and at the end of 3 months of treatment with the octreotide (somatostatin analog sms 201-995) 100 micrograms s.c. every 8 h. blood was withdrawn at 30-min intervals with the aid of a constant withdrawal pump. |
1992-09-15 |
2023-08-11 |
Not clear |
| D L Ewins, A Javaid, P B Coskeran, S Shah, J Butler, P H Deprez, J Miell, J Calam, J J Barrett, J M Dawso. Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly. The Quarterly journal of medicine. vol 83. issue 300. 1992-08-20. PMID:1631261. |
the development of gallstones is a well recognized complication of therapy with the long-acting somatostatin analogue, octreotide in patients with acromegaly. |
1992-08-20 |
2023-08-11 |
Not clear |
| K Mukada, T Uozumi, A Takechi, K Arita, T Yano, T Hirohata, J Onda, M Oht. Effect of long-term treatment with somatostatin analogue (SMS 201-995) on pituitary tumor shrinkage in acromegaly--report of two cases. Neurologia medico-chirurgica. vol 32. issue 4. 1992-08-19. PMID:1378566. |
effect of long-term treatment with somatostatin analogue (sms 201-995) on pituitary tumor shrinkage in acromegaly--report of two cases. |
1992-08-19 |
2023-08-11 |
Not clear |
| A Shimatsu, H Imura, M Irie, S Nakagawa, Y Goto, N Shimizu, R Takeda, Y Kato, S Saito, H Ibayash. [Long-term treatment of acromegaly and gigantism with octreotide (SMS 201-995)]. Nihon Naibunpi Gakkai zasshi. vol 68. issue 2. 1992-06-26. PMID:1592144. |
twenty-one patients with active acromegaly and two patients with pituitary gigantism were treated with the long-acting somatostatin analogue octreotide (100-600 micrograms/day, sc, two or three times daily or 300-1500 micrograms daily by intermittent sc infusion) for 9-63 months. |
1992-06-26 |
2023-08-11 |
Not clear |
| U Bürgi, R Seile. [Hypophyseal dysfunction and tumors]. Therapeutische Umschau. Revue therapeutique. vol 49. issue 3. 1992-06-18. PMID:1585268. |
alternative therapies are radiation treatment (in nonoperable patients or when hormone levels are persistently elevated after pituitary surgery) and drug treatment (dopamine agonists in hyperprolactinemia, somatostatin analogues in acromegaly). |
1992-06-18 |
2023-08-11 |
Not clear |
| E Ur, S J Mather, J Bomanji, D Ellison, K E Britton, A B Grossman, J A Wass, G M Besse. Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clinical endocrinology. vol 36. issue 2. 1992-05-22. PMID:1348978. |
pituitary imaging using a labelled somatostatin analogue in acromegaly. |
1992-05-22 |
2023-08-11 |
Not clear |